EMPLOYMENT AGREEMENTEmployment Agreement • February 4th, 2022 • Immunovant, Inc. • Biological products, (no disgnostic substances) • New York
This Employment Agreement (this “Agreement”) is entered into as of October 25, 2021, as amended, by and between William Macias, M.D. Ph.D. (the “Executive”) and IMVT Corporation (the “Company”).
ContractMaster Services Agreement • February 4th, 2022 • Immunovant, Inc. • Biological products, (no disgnostic substances) • New York
CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.
SAMSUNG BIOLOGICS CO., LTD. PRODUCT SERVICE AGREEMENT — COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Service Agreement • February 4th, 2022 • Immunovant, Inc. • Biological products, (no disgnostic substances)
This Product Service Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective Date”) by and between Immunovant Sciences GmbH a Swiss limited company with offices at Viaduktstrasse 8, 4051 Basel, Switzerland (“Client”) and Samsung Biologics Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
